NEW YORK (GenomeWeb News) - Aviva Systems Biology will produce antibodies that the Institute for Systems Biology will use to identify liver toxicity biomarkers, Aviva said Wednesday.
 
Under the terms of the collaborative agreement, Aviva will develop and produce the antibodies from a list of proteins provided by the ISB.
 
ISB will then assess the efficacy of these antibodies and will use them to find biomarker proteins that work as early liver toxicity biomarkers.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A fire at a Manchester hospital may have destroyed lab equipment and data, the Guardian reports.

Researchers generate a genetic database from skeletal remains from the 1845 Franklin Expedition to the Arctic, Live Science reports.

Researchers in China have begun another trial using CRISPR/Cas9 approaches in cancer patients, according to the Wall Street Journal.

In Science this week: human DNA found in sediments from archeological sites lacking bones, and more.